Due to the elicitation of vector-induced immunity limiting the usage of multiple booster vaccinations, the Ad26-TBS vaccine containing the same TB antigens was developed to bypass this issue, allowing for heterologous boosting of the Ad35-TBS vaccine (manuscript in preparation). The gene discussed is SALL1; the disease is tuberculosis.